Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Meningococcal disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    215 result(s) found for: Meningococcal disease. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-003504-79 Sponsor Protocol Number: V59P13 Start Date*: 2014-10-24
    Sponsor Name:Novartis Vaccines & Diagnostics, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Investigational Meningococcal ACWY Conjugate Vaccine when One Dose is Administered t...
    Medical condition: Novartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10027280 Meningococcal sepsis PT
    17.1 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    17.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    17.1 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    17.1 10021881 - Infections and infestations 10040081 Septicaemia meningococcal LLT
    17.1 10021881 - Infections and infestations 10040048 Sepsis meningococcal LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005189-48 Sponsor Protocol Number: MPS01 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute of Biological Products Meningococcal (Groups A and C) Polysaccharide Vacci...
    Medical condition: Meningococcal Disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005641-21 Sponsor Protocol Number: 112148 Start Date*: 2015-05-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study to assess the persistence of antibodies after one dose of GlaxoSmithKline Biologicals’ meningococcal serogroup ACWY conjugate vaccine (MenACWY-TT) given intramus...
    Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and/or Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004848 10070124 Neisseria meningitidis test positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002719-24 Sponsor Protocol Number: 112021 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, multi-center study to evaluate the long-term anti-body persistence at 1 year, 3 years and 5 years after the administration of one or two doses of GlaxoSmithKline (GSK) Biologicals...
    Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000048-28 Sponsor Protocol Number: EC002(Quad1) - C59P1 Start Date*: 2007-06-22
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: An open lable, randomised, controlled two centre study to evaluate the mucosal immune response to a quadrivalent meningococcal conjugate vaccine in healthy adults.
    Medical condition: Prevention of meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection LLT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001349-17 Sponsor Protocol Number: OVG2007/4 Start Date*: 2009-04-27
    Sponsor Name:University of Oxford
    Full Title: A single centre, open-label, randomised clinical trial to investigate Meningococcal serogroup A, C, W-135 and Y saccharide specific B cell response to a primary and a booster dose of the Meningococ...
    Medical condition: The Novartis Meningococcal A, C, W-135 and Y vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000104-38 Sponsor Protocol Number: MEQ00073 Start Date*: 2021-06-17
    Sponsor Name:Sanofi Pasteur
    Full Title: A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Boos...
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004341-36 Sponsor Protocol Number: MET55 Start Date*: 2020-12-04
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republ...
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019383-36 Sponsor Protocol Number: 670901 Start Date*: 2010-09-14
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A Phase IIIB, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants
    Medical condition: Active immunization for the prevention of invasive disease caused by Neisseria meningitidis serogroup C.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004461-41 Sponsor Protocol Number: MET59 Start Date*: 2020-02-14
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2025-000002-42 Sponsor Protocol Number: MEQ00086 Start Date*: 2025-04-10
    Sponsor Name:Sanofi Pasteur
    Full Title: A descriptive, Phase IV, open-label, single-arm multi-center study to assess the immunogenicity and safety of MenQuadfi® as a booster vaccine in healthy toddlers 12 to 23 months of age who had been...
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004609-42 Sponsor Protocol Number: OVG2017/08 Start Date*: 2018-02-21
    Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford
    Full Title: Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage
    Medical condition: Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    20.0 10021881 - Infections and infestations 10027268 Meningococcaemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003694-29 Sponsor Protocol Number: V72_37 Start Date*: 2013-03-26
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase 3b, Multi-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-risk Adults
    Medical condition: Healthy volunteers (Meningitis B)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004367-20 Sponsor Protocol Number: MET54 Start Date*: 2015-03-16
    Sponsor Name:Sanofi Pasteur
    Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10058858 Meningococcal bacteraemia PT
    18.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2025-000103-23 Sponsor Protocol Number: MEQ00075 Start Date*: 2025-04-09
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Phase I Open-Label, Age De-escalation Safety and Immunogenicity Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents, Children, Toddlers, and Infants in C...
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000283-23 Sponsor Protocol Number: 109495 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, controlled primary vaccination study to demonstrate the non-inferiority of meningococcal vaccine GSK134612 given intramuscularly versus Mencevax™ ACWY given subcutane...
    Medical condition: Meningococcal disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027275 Meningococcal infection, unspecified LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000282-20 Sponsor Protocol Number: 109069 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of meningococcal vaccine GSK134612 given intramuscularly ve...
    Medical condition: Meningococcal disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027275 Meningococcal infection, unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000924-13 Sponsor Protocol Number: VAN00010 Start Date*: 2023-12-21
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 yea...
    Medical condition: Bacterial infections and mycoses
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-019091-78 Sponsor Protocol Number: 2009_06 Start Date*: 2010-06-14
    Sponsor Name:University of Oxford
    Full Title: An observational study into the maintenance of seroprotection against Meningococcal serogroup C disease throughout childhood following a single dose of a conjugated Meningococcal serogroup C vaccin...
    Medical condition: Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018730-51 Sponsor Protocol Number: 113977 Start Date*: 2010-11-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-centre, controlled study to assess the long-term persistence of antibodies after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus-t...
    Medical condition: Vaccination of children 2 to 10 years of age against invasive disease caused by meningococcal serogroups A, C, W-135, and Y.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027274 Meningococcal infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Oct 25 22:11:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA